Emerging markets present a landscape of opportunity for equity investors despite macroeconomic headwinds. Click to read.
Confluent (NASDAQ:CFLT – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at William Blair in a ...
1d
Fintel on MSNWilliam Blair Upgrades DocuSign (DOCU)Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...
1d
Fintel on MSNWilliam Blair Initiates Coverage of Butterfly Network (BFLY) with Outperform RecommendationFintel reports that on March 17, 2025, William Blair initiated coverage of Butterfly Network (NYSE:BFLY) with a Outperform ...
William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...
Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...
JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...
The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...
We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...
The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.
William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results